CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 323 enrolled
Drug / intervention
Intravitreal Aflibercept Injection 2mgdrug
Likely dose
Intravitreal Aflibercept Injection 2mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00964795
NCT00964795Phase 3Completed
CompareCT.gov

An Open-label, Long-term, Safety and Tolerability Extension Study of Intravitreal VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration

Regeneron Pharmaceuticals·interventional·Posted Aug 25, 2009·Updated Mar 23, 2015

In Brief

A Phase 3 clinical trial evaluating Intravitreal Aflibercept Injection 2mg for Neovascular Age-related Macular Degeneration. Completed, enrolled 323 participants across 124 sites in 2 countries.

Detailed Summary

The primary objective is to assess long-term safety and tolerability of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in patients with neovascular AMD.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeovascular Age-related Macular Degeneration
CountriesCanada, United States
CollaboratorsBayer

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 25, 2009
Enrollment StartDec 1, 2009
Primary CompletionAug 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 16.9 years ago

Interventions

Intravitreal Aflibercept Injection 2mgdrug